{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T11:14:14Z","timestamp":1789902854460,"version":"4.0.1"},"reference-count":187,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract\n<\/jats:title>\n          <jats:sec>\n            <jats:title>Background\n<\/jats:title>\n            <jats:p>Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium\u2013glucose cotransporter 2 (SGLT2) inhibitors represent a new generation of antihyperglycemic agents that operate through mechanisms distinct from conventional diabetes treatments. Beyond their metabolic effects, these medications have demonstrated neuroprotective properties in preclinical studies. While clinical trials have explored their therapeutic potential in established neurodegenerative conditions, their role in disease prevention remains unclear. We conducted a network meta-analysis (NMA) to comprehensively evaluate the prophylactic benefits of these agents across multiple neurodegenerative diseases and identify the most promising preventive strategies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We systematically searched PubMed, Embase, ClinicalKey, Cochrane CENTRAL, ProQuest, ScienceDirect, Web of Science, and ClinicalTrials.gov through October 24th, 2024, for randomized controlled trials (RCTs) of GLP-1 receptor agonists or SGLT2 inhibitors. Our primary outcome was the incidence of seven major neurodegenerative diseases: Parkinson\u2019s disease, Alzheimer\u2019s disease, Lewy body dementia, multiple sclerosis, amyotrophic lateral sclerosis, frontotemporal dementia, and Huntington\u2019s disease. Secondary outcomes included safety profiles assessed through dropout rates. We performed a frequentist-based NMA and evaluated risk of bias with Risk of Bias tool. The main result of the primary outcome in the current study would be re-affirmed via sensitivity test with Bayesian-based NMA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Our analysis encompassed 22 RCTs involving 138,282 participants (mean age 64.8\u00a0years, 36.4% female). Among all investigated medications, only dapagliflozin demonstrated significant prophylactic benefits, specifically in preventing Parkinson\u2019s disease (odds ratio\u2009=\u20090.28, 95%\u00a0confidence intervals\u2009=\u20090.09 to 0.93) compared to controls. Neither GLP-1 receptor agonists nor other SGLT2 inhibitors showed significant preventive effects for any of the investigated neurodegenerative conditions. Drop-out rates were comparable across all treatments.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This comprehensive NMA reveals a novel and specific prophylactic effect of dapagliflozin against Parkinson\u2019s disease, representing a potential breakthrough in preventive neurology. The specificity of dapagliflozin\u2019s protective effect to Parkinson\u2019s disease might rely on its highly selective inhibition to SGLT2. These findings provide important direction for future research and could inform preventive strategies for populations at risk of Parkinson\u2019s disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>PROSPERO CRD42021252381.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12916-025-04018-w","type":"journal-article","created":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T23:01:47Z","timestamp":1743980507000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: evidence from a network meta-analysis"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5761-7800","authenticated-orcid":false,"given":"Ping-Tao","family":"Tseng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-Yan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Wei","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Ming","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre F.","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendon","family":"Stubbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Te","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiann-Jy","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Pin","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0798-5028","authenticated-orcid":false,"given":"Yow-Ling","family":"Shiue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1138-5586","authenticated-orcid":false,"given":"Chih-Sung","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"issue":"12","key":"4018_CR1","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S2213-8587(22)00247-9","volume":"10","author":"A Avogaro","year":"2022","unstructured":"Avogaro A, de Kreutzenberg SV, Morieri ML, Fadini GP, Del Prato S. Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history. Lancet Diabetes Endocrinol. 2022;10(12):882\u20139.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"4018_CR2","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1080\/02699052.2019.1587000","volume":"33","author":"D Erbil","year":"2019","unstructured":"Erbil D, Eren CY, Demirel C, Kucuker MU, Solaroglu I, Eser HY. GLP-1\u2019s role in neuroprotection: a systematic review. Brain Inj. 2019;33(6):734\u2013819.","journal-title":"Brain Inj"},{"issue":"7","key":"4018_CR3","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s40265-014-0225-5","volume":"74","author":"GL Plosker","year":"2014","unstructured":"Plosker GL. Canagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs. 2014;74(7):807\u201324.","journal-title":"Drugs"},{"issue":"17","key":"4018_CR4","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.117.030012","volume":"136","author":"Y Lytvyn","year":"2017","unstructured":"Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI. Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation. 2017;136(17):1643\u201358.","journal-title":"Circulation"},{"issue":"5S","key":"4018_CR5","first-page":"S1","volume":"102","author":"Kidney Disease: Improving Global Outcomes Diabetes Work G","year":"2022","unstructured":"Kidney Disease: Improving Global Outcomes Diabetes Work G. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5S):S1\u2013127.","journal-title":"Kidney Int"},{"issue":"1","key":"4018_CR6","doi-asserted-by":"publisher","first-page":"5912","DOI":"10.1038\/s41467-024-50199-y","volume":"15","author":"HC Pan","year":"2024","unstructured":"Pan HC, Chen JY, Chen HY, Yeh FY, Sun CY, Huang TT, et al. GLP-1 receptor agonists\u2019 impact on cardio-renal outcomes and mortality in T2D with acute kidney disease. Nat Commun. 2024;15(1):5912.","journal-title":"Nat Commun"},{"issue":"13","key":"4018_CR7","doi-asserted-by":"publisher","first-page":"3729","DOI":"10.3390\/jcm13133729","volume":"13","author":"J Fessel","year":"2024","unstructured":"Fessel J. All GLP-1 agonists should, theoretically, cure Alzheimer\u2019s dementia but dulaglutide might be more effective than the others. J Clin Med. 2024;13(13):3729.","journal-title":"J Clin Med"},{"key":"4018_CR8","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.neuropharm.2018.11.002","volume":"144","author":"M Holubova","year":"2019","unstructured":"Holubova M, Hruba L, Popelova A, Bencze M, Prazienkova V, Gengler S, et al. Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of beta-amyloid pathology. Neuropharmacology. 2019;144:377\u201387.","journal-title":"Neuropharmacology"},{"key":"4018_CR9","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.neuropharm.2014.07.015","volume":"86","author":"PL McClean","year":"2014","unstructured":"McClean PL, Holscher C. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer\u2019s disease. Neuropharmacology. 2014;86:241\u201358.","journal-title":"Neuropharmacology"},{"issue":"1","key":"4018_CR10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S1474-4422(23)00378-2","volume":"23","author":"A McGarry","year":"2024","unstructured":"McGarry A, Rosanbalm S, Leinonen M, Olanow CW, To D, Bell A, et al. Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2024;23(1):37\u201345.","journal-title":"Lancet Neurol"},{"issue":"3","key":"4018_CR11","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3233\/JPD-140364","volume":"4","author":"I Aviles-Olmos","year":"2014","unstructured":"Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Kahan J, Ell P, et al. Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson\u2019s disease. J Parkinsons Dis. 2014;4(3):337\u201344.","journal-title":"J Parkinsons Dis"},{"key":"4018_CR12","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3389\/fnagi.2016.00108","volume":"8","author":"M Gejl","year":"2016","unstructured":"Gejl M, Gjedde A, Egefjord L, Moller A, Hansen SB, Vang K, et al. Alzheimer\u2019s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial. Front Aging Neurosci. 2016;8:108.","journal-title":"Front Aging Neurosci"},{"issue":"7","key":"4018_CR13","first-page":"CD012990","volume":"7","author":"CA Mulvaney","year":"2020","unstructured":"Mulvaney CA, Duarte GS, Handley J, Evans DJ, Menon S, Wyse R, et al. GLP-1 receptor agonists for Parkinson\u2019s disease. Cochrane Database Syst Rev. 2020;7(7):CD012990.","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"4018_CR14","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1172\/JCI78371","volume":"124","author":"LL Baggio","year":"2014","unstructured":"Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight. J Clin Invest. 2014;124(10):4223\u20136.","journal-title":"J Clin Invest"},{"key":"4018_CR15","doi-asserted-by":"publisher","first-page":"106472","DOI":"10.1016\/j.nbd.2024.106472","volume":"194","author":"C Zhou","year":"2024","unstructured":"Zhou C, You J, Guan X, Guo T, Wu J, Wu H, et al. Microstructural alterations of the hypothalamus in Parkinson\u2019s disease and probable REM sleep behavior disorder. Neurobiol Dis. 2024;194:106472.","journal-title":"Neurobiol Dis"},{"issue":"5","key":"4018_CR16","doi-asserted-by":"publisher","first-page":"e047993","DOI":"10.1136\/bmjopen-2020-047993","volume":"11","author":"N Vijiaratnam","year":"2021","unstructured":"Vijiaratnam N, Girges C, Auld G, Chau M, Maclagan K, King A, et al. Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson\u2019s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: the \u201cExenatide-PD3\u201d study. BMJ Open. 2021;11(5):e047993.","journal-title":"BMJ Open"},{"key":"4018_CR17","doi-asserted-by":"publisher","first-page":"107220","DOI":"10.1016\/j.parkreldis.2024.107220","volume":"130","author":"MB Albuquerque","year":"2025","unstructured":"Albuquerque MB, Nunes L, Oliveira Maldonado JV, Melo Ferreira DG, Margato MM, Rabelo LV, et al. GLP-1 receptor agonists for Parkinson\u2019s disease: an updated meta-analysis. Parkinsonism Relat Disord. 2025;130:107220.","journal-title":"Parkinsonism Relat Disord"},{"key":"4018_CR18","doi-asserted-by":"publisher","first-page":"174715","DOI":"10.1016\/j.ejphar.2021.174715","volume":"918","author":"E Abdollahi","year":"2022","unstructured":"Abdollahi E, Keyhanfar F, Delbandi AA, Falak R, Hajimiresmaiel SJ, Shafiei M. Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-kappaB activation in human endothelial cells and differentiated macrophages. Eur J Pharmacol. 2022;918:174715.","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"4018_CR19","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"12","key":"4018_CR20","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089\u201398.","journal-title":"N Engl J Med"},{"issue":"10193","key":"4018_CR21","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121\u201330.","journal-title":"Lancet"},{"issue":"13","key":"4018_CR22","doi-asserted-by":"publisher","first-page":"4805","DOI":"10.3390\/ijerph17134805","volume":"17","author":"SY Wang","year":"2020","unstructured":"Wang SY, Wu SL, Chen TC, Chuang CS. Antidiabetic agents for treatment of Parkinson\u2019s disease: a meta-analysis. Int J Environ Res Public Health. 2020;17(13):4805.","journal-title":"Int J Environ Res Public Health"},{"issue":"10","key":"4018_CR23","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1111\/dom.13373","volume":"20","author":"B Cao","year":"2018","unstructured":"Cao B, Rosenblat JD, Brietzke E, Park C, Lee Y, Musial N, et al. Comparative efficacy and acceptability of antidiabetic agents for Alzheimer\u2019s disease and mild cognitive impairment: a systematic review and network meta-analysis. Diabetes Obes Metab. 2018;20(10):2467\u201371.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"4018_CR24","doi-asserted-by":"publisher","first-page":"572","DOI":"10.7861\/clinmedicine.9-6-572","volume":"9","author":"L Borysiewicz","year":"2009","unstructured":"Borysiewicz L. Prevention is better than cure. Clin Med (Lond). 2009;9(6):572\u201383.","journal-title":"Clin Med (Lond)"},{"issue":"3","key":"4018_CR25","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/j.1582-4934.2010.01010.x","volume":"14","author":"KA Jellinger","year":"2010","unstructured":"Jellinger KA. Basic mechanisms of neurodegeneration: a critical update. J Cell Mol Med. 2010;14(3):457\u201387.","journal-title":"J Cell Mol Med"},{"issue":"7","key":"4018_CR26","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1111\/jgs.18306","volume":"71","author":"H Tang","year":"2023","unstructured":"Tang H, Shao H, Shaaban CE, Yang K, Brown J, Anton S, et al. Newer glucose-lowering drugs and risk of dementia: a systematic review and meta-analysis of observational studies. J Am Geriatr Soc. 2023;71(7):2096\u2013106.","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"4018_CR27","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/dom.15331","volume":"26","author":"A Kuate Defo","year":"2024","unstructured":"Kuate Defo A, Bakula V, Pisaturo A, Labos C, Wing SS, Daskalopoulou SS. Diabetes, antidiabetic medications and risk of dementia: a systematic umbrella review and meta-analysis. Diabetes Obes Metab. 2024;26(2):441\u201362.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"4018_CR28","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1002\/mdc3.13893","volume":"10","author":"H Tang","year":"2023","unstructured":"Tang H, Lu Y, Okun MS, Donahoo WT, Ramirez-Zamora A, Wang F, et al. Meta-analysis of association between newer glucose-lowering drugs and risk of Parkinson\u2019s disease. Mov Disord Clin Pract. 2023;10(11):1659\u201365.","journal-title":"Mov Disord Clin Pract"},{"issue":"9994","key":"4018_CR29","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/S0140-6736(15)61478-7","volume":"386","author":"JP Higgins","year":"2015","unstructured":"Higgins JP, Welton NJ. Network meta-analysis: a norm for comparative effectiveness? Lancet. 2015;386(9994):628\u201330.","journal-title":"Lancet"},{"issue":"11","key":"4018_CR30","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777\u201384.","journal-title":"Ann Intern Med"},{"key":"4018_CR31","doi-asserted-by":"crossref","unstructured":"Jaiswal V, Mashkoor Y, Raj N, Rajak K, Jaiswal A, Fonarow GC. Association between SGLT2 inhibitors and risk of dementia and Parkinson's disease: a meta-analysis of 12 randomized controlled trials.\u00a0Am J Med. 2024;137(11):1136\u201341.","DOI":"10.1016\/j.amjmed.2024.06.030"},{"issue":"1","key":"4018_CR32","doi-asserted-by":"publisher","first-page":"102943","DOI":"10.1016\/j.dsx.2024.102943","volume":"18","author":"M Banerjee","year":"2024","unstructured":"Banerjee M, Pal R, Maisnam I, Mukhopadhyay S. GLP-1 receptor agonists, SGLT2 inhibitors and noncardiovascular mortality in type 2 diabetes: Insights from a meta-analysis. Diabetes Metab Syndr. 2024;18(1):102943.","journal-title":"Diabetes Metab Syndr"},{"issue":"9","key":"4018_CR33","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.5664\/jcsm.9326","volume":"17","author":"K Maski","year":"2021","unstructured":"Maski K, Trotti LM, Kotagal S, Robert Auger R, Swick TJ, Rowley JA, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. J Clin Sleep Med. 2021;17(9):1895\u2013945.","journal-title":"J Clin Sleep Med"},{"issue":"Pt 2","key":"4018_CR34","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1093\/brain\/aws009","volume":"136","author":"I Aviles-Olmos","year":"2013","unstructured":"Aviles-Olmos I, Limousin P, Lees A, Foltynie T. Parkinson\u2019s disease, insulin resistance and novel agents of neuroprotection. Brain. 2013;136(Pt 2):374\u201384.","journal-title":"Brain"},{"issue":"5","key":"4018_CR35","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2174\/1871527322666230330122444","volume":"23","author":"M Ciocca","year":"2024","unstructured":"Ciocca M, Pizzamiglio C. Clinical benefits of therapeutic interventions targeting mitochondria in Parkinson\u2019s disease patients. CNS Neurol Disord Drug Targets. 2024;23(5):554\u201361.","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"1","key":"4018_CR36","doi-asserted-by":"publisher","first-page":"16","DOI":"10.17925\/EE.2023.19.1.16","volume":"19","author":"IM Colin","year":"2023","unstructured":"Colin IM, Szczepanski LW, Gerard AC, Elosegi JA. Emerging evidence for the use of antidiabetic drugs, glucagon-like peptide 1 receptor agonists, for the treatment of Alzheimer\u2019s disease. touchREV Endocrinol. 2023;19(1):16\u201324.","journal-title":"touchREV Endocrinol"},{"key":"4018_CR37","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.clineuro.2017.04.014","volume":"158","author":"O Eberhardt","year":"2017","unstructured":"Eberhardt O, Topka H. Neurological outcomes of antidiabetic therapy: what the neurologist should know. Clin Neurol Neurosurg. 2017;158:60\u20136.","journal-title":"Clin Neurol Neurosurg"},{"issue":"6","key":"4018_CR38","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1080\/13543784.2020.1764534","volume":"29","author":"EJ Glotfelty","year":"2020","unstructured":"Glotfelty EJ, Olson L, Karlsson TE, Li Y, Greig NH. Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson\u2019s disease. Expert Opin Investig Drugs. 2020;29(6):595\u2013602.","journal-title":"Expert Opin Investig Drugs"},{"issue":"10","key":"4018_CR39","doi-asserted-by":"publisher","first-page":"871","DOI":"10.2165\/11635890-000000000-00000","volume":"26","author":"C Holscher","year":"2012","unstructured":"Holscher C. Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection. CNS Drugs. 2012;26(10):871\u201382.","journal-title":"CNS Drugs"},{"issue":"1","key":"4018_CR40","doi-asserted-by":"publisher","first-page":"777","DOI":"10.3233\/ADR-230181","volume":"8","author":"Y Liang","year":"2024","unstructured":"Liang Y, Dore V, Rowe CC, Krishnadas N. Clinical evidence for GLP-1 receptor agonists in Alzheimer\u2019s disease: a systematic review. J Alzheimers Dis Rep. 2024;8(1):777\u201389.","journal-title":"J Alzheimers Dis Rep"},{"key":"4018_CR41","doi-asserted-by":"publisher","first-page":"204062232210869","DOI":"10.1177\/20406223221086996","volume":"13","author":"T Tharmaraja","year":"2022","unstructured":"Tharmaraja T, Ho JSY, Sia CH, Lim NA, Chong YF, Lim AYL, et al. Sodium-glucose cotransporter 2 inhibitors and neurological disorders: a scoping review. Ther Adv Chronic Dis. 2022;13:20406223221086996.","journal-title":"Ther Adv Chronic Dis"},{"issue":"2","key":"4018_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-024537","volume":"9","author":"R Phillips","year":"2019","unstructured":"Phillips R, Hazell L, Sauzet O, Cornelius V. Analysis and reporting of adverse events in randomised controlled trials: a review. BMJ Open. 2019;9(2): e024537.","journal-title":"BMJ Open"},{"key":"4018_CR43","doi-asserted-by":"crossref","unstructured":"Higgins J, Green S. Cochrane handbook for systematic reviews of interventions version 5.0.2. The Cochrane Collaboration; 2009.","DOI":"10.1002\/9780470712184"},{"key":"4018_CR44","doi-asserted-by":"crossref","unstructured":"Suescun J, Chandra S, Schiess MC. Chapter 13 - the role of neuroinflammation in neurodegenerative disorders. In: Actor JK, Smith KC, editors. Translational inflammation: a volume in perspectives in translational cell biology. edn. Houston: Academic Press; 2019. p. 241\u201367.","DOI":"10.1016\/B978-0-12-813832-8.00013-3"},{"issue":"2","key":"4018_CR45","first-page":"164","volume":"16","author":"AM Koenig","year":"2018","unstructured":"Koenig AM, Nobuhara CK, Williams VJ, Arnold SE. Biomarkers in Alzheimer\u2019s, frontotemporal, lewy body, and vascular dementias. Focus (Am Psychiatr Publ). 2018;16(2):164\u201372.","journal-title":"Focus (Am Psychiatr Publ)"},{"key":"4018_CR46","doi-asserted-by":"crossref","unstructured":"Chaimani A, Caldwell DM, Li T, Higgins JPT, Salanti G. Chapter 11: undertaking network meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston MS, Li T, Page M, et al., editors. Cochrane handbook for systematic reviews of interventions. London: Cochrane; 2018. p. 7.","DOI":"10.1002\/9781119536604.ch11"},{"issue":"16","key":"4018_CR47","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"issue":"2","key":"4018_CR48","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384(2):129\u201339.","journal-title":"N Engl J Med"},{"issue":"2","key":"4018_CR49","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117\u201328.","journal-title":"N Engl J Med"},{"issue":"9982","key":"4018_CR50","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1016\/S0140-6736(15)60936-9","volume":"385","author":"L Blonde","year":"2015","unstructured":"Blonde L, Jendle J, Gross J, Woo V, Jiang H, Fahrbach JL, et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet. 2015;385(9982):2057\u201366.","journal-title":"Lancet"},{"issue":"15","key":"4018_CR51","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425\u201335.","journal-title":"N Engl J Med"},{"issue":"3","key":"4018_CR52","doi-asserted-by":"publisher","first-page":"604","DOI":"10.2337\/dc10-1900","volume":"34","author":"B Gallwitz","year":"2011","unstructured":"Gallwitz B, Bohmer M, Segiet T, Molle A, Milek K, Becker B, et al. Exenatide twice daily versus premixed insulin aspart 70\/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia. Diabetes Care. 2011;34(3):604\u20136.","journal-title":"Diabetes Care"},{"issue":"15","key":"4018_CR53","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"10157","key":"4018_CR54","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S, D\u2019Agostino RB Sr, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519\u201329.","journal-title":"Lancet"},{"issue":"13","key":"4018_CR55","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228\u201339.","journal-title":"N Engl J Med"},{"issue":"9","key":"4018_CR56","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841\u201351.","journal-title":"N Engl J Med"},{"issue":"7","key":"4018_CR57","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1111\/dom.15041","volume":"25","author":"L Ji","year":"2023","unstructured":"Ji L, Lu Y, Li Q, Fu L, Luo Y, Lei T, et al. Efficacy and safety of empagliflozin in combination with insulin in Chinese patients with type 2 diabetes and insufficient glycaemic control: a phase III, randomized, double-blind, placebo-controlled, parallel study. Diabetes Obes Metab. 2023;25(7):1839\u201348.","journal-title":"Diabetes Obes Metab"},{"issue":"19","key":"4018_CR58","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"issue":"4","key":"4018_CR59","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"21","key":"4018_CR60","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"7","key":"4018_CR61","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"24","key":"4018_CR62","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"23","key":"4018_CR63","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kober LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247\u201357.","journal-title":"N Engl J Med"},{"issue":"2","key":"4018_CR64","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"E-KCG The","year":"2023","unstructured":"The E-KCG, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327.","journal-title":"N Engl J Med."},{"issue":"22","key":"4018_CR65","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"2","key":"4018_CR66","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/jrsm.12","volume":"1","author":"M Borenstein","year":"2010","unstructured":"Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1(2):97\u2013111.","journal-title":"Res Synth Methods"},{"issue":"4","key":"4018_CR67","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/jrsm.1373","volume":"10","author":"RK Owen","year":"2019","unstructured":"Owen RK, Bradbury N, Xin Y, Cooper N, Sutton A. MetaInsight: an interactive web-based tool for analyzing, interrogating, and visualizing network meta-analyses using R-shiny and netmeta. Res Synth Methods. 2019;10(4):569\u201381.","journal-title":"Res Synth Methods"},{"issue":"8","key":"4018_CR68","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010983","volume":"6","author":"J Cheng","year":"2016","unstructured":"Cheng J, Pullenayegum E, Marshall JK, Iorio A, Thabane L. Impact of including or excluding both-armed zero-event studies on using standard meta-analysis methods for rare event outcome: a simulation study. BMJ Open. 2016;6(8): e010983.","journal-title":"BMJ Open"},{"issue":"28","key":"4018_CR69","doi-asserted-by":"publisher","first-page":"4861","DOI":"10.1002\/sim.6301","volume":"33","author":"AC Brockhaus","year":"2014","unstructured":"Brockhaus AC, Bender R, Skipka G. The Peto odds ratio viewed as a new effect measure. Stat Med. 2014;33(28):4861\u201374.","journal-title":"Stat Med"},{"key":"4018_CR70","unstructured":"Converting among effect sizes. https:\/\/www.meta-analysis.com\/downloads\/Meta-analysis%20Converting%20among%20effect%20sizes.pdf."},{"issue":"7\u20138","key":"4018_CR71","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/sim.3767","volume":"29","author":"S Dias","year":"2010","unstructured":"Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010;29(7\u20138):932\u201344.","journal-title":"Stat Med"},{"key":"4018_CR72","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jclinepi.2023.02.016","volume":"157","author":"CR Nevill","year":"2023","unstructured":"Nevill CR, Cooper NJ, Sutton AJ. A multifaceted graphical display, including treatment ranking, was developed to aid interpretation of network meta-analysis. J Clin Epidemiol. 2023;157:83\u201391.","journal-title":"J Clin Epidemiol"},{"key":"4018_CR73","unstructured":"Dias S, Ades AE, Welton NJ, Jansen JP, Sutton AJ. Chapter 3: Model fit, model comparison and outlier detection. In: Scott M, Barnett V, editors. Network meta-anlaysis for decision-making. edn. Chichester: John Wiley & Sons Ltd; 2002. p. 59\u201392."},{"issue":"2","key":"4018_CR74","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2337\/dc17-0417","volume":"41","author":"AJ Ahmann","year":"2018","unstructured":"Ahmann AJ, Capehorn M, Charpentier G, Dotta F, Henkel E, Lingvay I, et al. fficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018;41(2):258\u201366.","journal-title":"Diabetes Care"},{"issue":"6","key":"4018_CR75","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jsps.2022.03.005","volume":"30","author":"S Ahmed","year":"2022","unstructured":"Ahmed S, El-Sayed MM, Kandeil MA, Khalaf MM. Empagliflozin attenuates neurodegeneration through antioxidant, anti-inflammatory, and modulation of alpha-synuclein and Parkin levels in rotenone-induced Parkinson\u2019s disease in rats. Saudi Pharm J. 2022;30(6):863\u201373.","journal-title":"Saudi Pharm J"},{"issue":"5","key":"4018_CR76","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","volume":"5","author":"B Ahren","year":"2017","unstructured":"Ahren B, Masmiquel L, Kumar H, Sargin M, Karsbol JD, Jacobsen SH, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5(5):341\u201354.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4018_CR77","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.neuroscience.2015.05.023","volume":"300","author":"FM An","year":"2015","unstructured":"An FM, Chen S, Xu Z, Yin L, Wang Y, Liu AR, et al. Glucagon-like peptide-1 regulates mitochondrial biogenesis and tau phosphorylation against advanced glycation end product-induced neuronal insult: studies in vivo and in vitro. Neuroscience. 2015;300:75\u201384.","journal-title":"Neuroscience"},{"issue":"9","key":"4018_CR78","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.2337\/dc19-0749","volume":"42","author":"VR Aroda","year":"2019","unstructured":"Aroda VR, Rosenstock J, Terauchi Y, Altuntas Y, Lalic NM, Morales Villegas EC, et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019;42(9):1724\u201332.","journal-title":"Diabetes Care"},{"issue":"4","key":"4018_CR79","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1001\/jamaneurol.2018.4304","volume":"76","author":"D Athauda","year":"2019","unstructured":"Athauda D, Gulyani S, Karnati HK, Li Y, Tweedie D, Mustapic M, et al. Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients with Parkinson disease: a secondary analysis of the exenatide-PD trial. JAMA Neurol. 2019;76(4):420\u20139.","journal-title":"JAMA Neurol"},{"issue":"2","key":"4018_CR80","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3233\/JPD-181329","volume":"8","author":"D Athauda","year":"2018","unstructured":"Athauda D, Maclagan K, Budnik N, Zampedri L, Hibbert S, Skene SS, et al. What effects might exenatide have on non-motor symptoms in Parkinson\u2019s disease: a post hoc analysis. J Parkinsons Dis. 2018;8(2):247\u201358.","journal-title":"J Parkinsons Dis"},{"issue":"10103","key":"4018_CR81","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","volume":"390","author":"D Athauda","year":"2017","unstructured":"Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, et al. Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10103):1664\u201375.","journal-title":"Lancet"},{"issue":"3","key":"4018_CR82","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3233\/JPD-171192","volume":"7","author":"D Athauda","year":"2017","unstructured":"Athauda D, Wyse R, Brundin P, Foltynie T. Is exenatide a treatment for Parkinson\u2019s disease? J Parkinsons Dis. 2017;7(3):451\u20138.","journal-title":"J Parkinsons Dis"},{"issue":"6","key":"4018_CR83","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1172\/JCI68295","volume":"123","author":"I Aviles-Olmos","year":"2013","unstructured":"Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Ell P, Soderlund T, et al. Exenatide and the treatment of patients with Parkinson\u2019s disease. J Clin Invest. 2013;123(6):2730\u20136.","journal-title":"J Clin Invest"},{"issue":"3","key":"4018_CR84","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s12640-019-9998-3","volume":"35","author":"GA Badawi","year":"2019","unstructured":"Badawi GA, Abd El Fattah MA, Zaki HF, El Sayed MI. Sitagliptin and liraglutide modulate L-dopa effect and attenuate dyskinetic movements in rotenone-lesioned rats. Neurotox Res. 2019;35(3):635\u201353.","journal-title":"Neurotox Res"},{"issue":"9733","key":"4018_CR85","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","volume":"375","author":"CJ Bailey","year":"2010","unstructured":"Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9733):2223\u201333.","journal-title":"Lancet"},{"issue":"5","key":"4018_CR86","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","volume":"2","author":"AH Barnett","year":"2014","unstructured":"Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2(5):369\u201384.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"4018_CR87","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.2337\/dc18-0343","volume":"41","author":"JB Buse","year":"2018","unstructured":"Buse JB, Garg SK, Rosenstock J, Bailey TS, Banks P, Bode BW, et al. Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American inTandem1 study. Diabetes Care. 2018;41(9):1970\u201380.","journal-title":"Diabetes Care"},{"issue":"9683","key":"4018_CR88","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","volume":"374","author":"JB Buse","year":"2009","unstructured":"Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39\u201347.","journal-title":"Lancet"},{"key":"4018_CR89","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.neuroscience.2014.02.022","volume":"277","author":"HY Cai","year":"2014","unstructured":"Cai HY, Holscher C, Yue XH, Zhang SX, Wang XH, Qiao F, et al. Lixisenatide rescues spatial memory and synaptic plasticity from amyloid beta protein-induced impairments in rats. Neuroscience. 2014;277:6\u201313.","journal-title":"Neuroscience"},{"issue":"7","key":"4018_CR90","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.2337\/dc14-0315","volume":"38","author":"WT Cefalu","year":"2015","unstructured":"Cefalu WT, Leiter LA, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ. Dapagliflozin\u2019s effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. Diabetes Care. 2015;38(7):1218\u201327.","journal-title":"Diabetes Care"},{"issue":"7","key":"4018_CR91","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s00125-013-2905-1","volume":"56","author":"B Charbonnel","year":"2013","unstructured":"Charbonnel B, Steinberg H, Eymard E, Xu L, Thakkar P, Prabhu V, et al. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial. Diabetologia. 2013;56(7):1503\u201311.","journal-title":"Diabetologia"},{"issue":"8","key":"4018_CR92","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1007\/s11064-017-2250-8","volume":"42","author":"S Chen","year":"2017","unstructured":"Chen S, Sun J, Zhao G, Guo A, Chen Y, Fu R, et al. Liraglutide improves water maze learning and memory performance while reduces hyperphosphorylation of tau and neurofilaments in APP\/PS1\/Tau triple transgenic mice. Neurochem Res. 2017;42(8):2326\u201335.","journal-title":"Neurochem Res"},{"issue":"6","key":"4018_CR93","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1111\/dom.15019","volume":"25","author":"DZI Cherney","year":"2023","unstructured":"Cherney DZI, Ferrannini E, Umpierrez GE, Peters AL, Rosenstock J, Powell DR, et al. Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease. Diabetes Obes Metab. 2023;25(6):1646\u201357.","journal-title":"Diabetes Obes Metab"},{"issue":"10278","key":"4018_CR94","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies M, Faerch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971\u201384.","journal-title":"Lancet."},{"issue":"2","key":"4018_CR95","doi-asserted-by":"publisher","first-page":"222","DOI":"10.2337\/dc14-2883","volume":"39","author":"MJ Davies","year":"2016","unstructured":"Davies MJ, Bain SC, Atkin SL, Rossing P, Scott D, Shamkhalova MS, et al. Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial. Diabetes Care. 2016;39(2):222\u201330.","journal-title":"Diabetes Care"},{"issue":"7","key":"4018_CR96","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.9676","volume":"314","author":"MJ Davies","year":"2015","unstructured":"Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjoth TV, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314(7):687\u201399.","journal-title":"JAMA"},{"issue":"9","key":"4018_CR97","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1007\/s40618-024-02320-7","volume":"47","author":"A Dei Cas","year":"2024","unstructured":"Dei Cas A, Micheli MM, Aldigeri R, Gardini S, Ferrari-Pellegrini F, Perini M, et al. Long-acting exenatide does not prevent cognitive decline in mild cognitive impairment: a proof-of-concept clinical trial. J Endocrinol Invest. 2024;47(9):2339\u201349.","journal-title":"J Endocrinol Invest"},{"issue":"9951","key":"4018_CR98","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/S0140-6736(14)60976-4","volume":"384","author":"KM Dungan","year":"2014","unstructured":"Dungan KM, Povedano ST, Forst T, Gonzalez JG, Atisso C, Sealls W, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014;384(9951):1349\u201357.","journal-title":"Lancet"},{"issue":"5","key":"4018_CR99","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/dom.12634","volume":"18","author":"KM Dungan","year":"2016","unstructured":"Dungan KM, Weitgasser R, Perez Manghi F, Pintilei E, Fahrbach JL, Jiang HH, et al. A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8). Diabetes Obes Metab. 2016;18(5):475\u201382.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"4018_CR100","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/oby.23395","volume":"30","author":"CK Fox","year":"2022","unstructured":"Fox CK, Clark JM, Rudser KD, Ryder JR, Gross AC, Nathan BM, et al. Exenatide for weight-loss maintenance in adolescents with severe obesity: a randomized, placebo-controlled trial. Obesity (Silver Spring). 2022;30(5):1105\u201315.","journal-title":"Obesity (Silver Spring)"},{"issue":"7","key":"4018_CR101","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.2337\/dc21-2656","volume":"45","author":"JP Frias","year":"2022","unstructured":"Frias JP, Choi J, Rosenstock J, Popescu L, Niemoeller E, Muehlen-Bartmer I, et al. Efficacy and safety of once-weekly efpeglenatide monotherapy versus placebo in type 2 diabetes: the AMPLITUDE-M randomized controlled trial. Diabetes Care. 2022;45(7):1592\u2013600.","journal-title":"Diabetes Care"},{"issue":"10400","key":"4018_CR102","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S0140-6736(23)01302-8","volume":"402","author":"JP Frias","year":"2023","unstructured":"Frias JP, Hsia S, Eyde S, Liu R, Ma X, Konig M, et al. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet. 2023;402(10400):472\u201383.","journal-title":"Lancet"},{"issue":"4","key":"4018_CR103","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1111\/dom.13631","volume":"21","author":"S Gallo","year":"2019","unstructured":"Gallo S, Charbonnel B, Goldman A, Shi H, Huyck S, Darekar A, et al. Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial. Diabetes Obes Metab. 2019;21(4):1027\u201336.","journal-title":"Diabetes Obes Metab"},{"issue":"9833","key":"4018_CR104","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1016\/S0140-6736(12)60479-6","volume":"379","author":"B Gallwitz","year":"2012","unstructured":"Gallwitz B, Guzman J, Dotta F, Guerci B, Simo R, Basson BR, et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. Lancet. 2012;379(9833):2270\u20138.","journal-title":"Lancet"},{"issue":"9662","key":"4018_CR105","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S0140-6736(08)61246-5","volume":"373","author":"A Garber","year":"2009","unstructured":"Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373(9662):473\u201381.","journal-title":"Lancet"},{"issue":"10","key":"4018_CR106","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083\u201391.","journal-title":"Nat Med"},{"issue":"1","key":"4018_CR107","doi-asserted-by":"publisher","first-page":"17490","DOI":"10.1038\/s41598-017-17718-y","volume":"7","author":"M Gejl","year":"2017","unstructured":"Gejl M, Brock B, Egefjord L, Vang K, Rungby J, Gjedde A. Blood-brain glucose transfer in Alzheimer\u2019s disease: effect of GLP-1 analog treatment. Sci Rep. 2017;7(1):17490.","journal-title":"Sci Rep"},{"issue":"10","key":"4018_CR108","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","volume":"385","author":"HC Gerstein","year":"2021","unstructured":"Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021;385(10):896\u2013907.","journal-title":"N Engl J Med"},{"issue":"12","key":"4018_CR109","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.2337\/dc14-1625","volume":"38","author":"F Giorgino","year":"2015","unstructured":"Giorgino F, Benroubi M, Sun JH, Zimmermann AG, Pechtner V. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care. 2015;38(12):2241\u20139.","journal-title":"Diabetes Care"},{"issue":"12","key":"4018_CR110","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/S2213-8587(23)00253-X","volume":"11","author":"Group RC","year":"2023","unstructured":"Group RC. Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet Diabetes Endocrinol. 2023;11(12):905\u201314.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"4018_CR111","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s13300-017-0337-5","volume":"9","author":"G Grunberger","year":"2018","unstructured":"Grunberger G, Camp S, Johnson J, Huyck S, Terra SG, Mancuso JP, et al. Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: the VERTIS RENAL randomized study. Diabetes Ther. 2018;9(1):49\u201366.","journal-title":"Diabetes Ther"},{"issue":"1","key":"4018_CR112","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/WNR.0000000000000490","volume":"27","author":"L Han","year":"2016","unstructured":"Han L, Holscher C, Xue GF, Li G, Li D. A novel dual-glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist is neuroprotective in transient focal cerebral ischemia in the rat. NeuroReport. 2016;27(1):23\u201332.","journal-title":"NeuroReport"},{"key":"4018_CR113","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.diabres.2017.06.013","volume":"131","author":"PD Home","year":"2017","unstructured":"Home PD, Ahren B, Reusch JEB, Rendell M, Weissman PN, Cirkel DT, et al. Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long-term efficacy with or without rescue therapy. Diabetes Res Clin Pract. 2017;131:49\u201360.","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"4018_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2024.101581","volume":"50","author":"B Hong","year":"2024","unstructured":"Hong B, Lee H, Choi A, Kim WJ, Cho YM, Yon DK, et al. Sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase IV inhibitors and risk of dementia among patients with type 2 diabetes and comorbid mental disorders: a population-based cohort study. Diabetes Metab. 2024;50(6): 101581.","journal-title":"Diabetes Metab"},{"issue":"11","key":"4018_CR115","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/nrneurol.2017.140","volume":"13","author":"J Jankovic","year":"2017","unstructured":"Jankovic J. Parkinson disease: exenatide - a drug for diabetes and Parkinson disease? Nat Rev Neurol. 2017;13(11):643\u20134.","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"4018_CR116","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jacc.2017.06.016","volume":"70","author":"JL Januzzi Jr","year":"2017","unstructured":"Januzzi JL Jr, Butler J, Jarolim P, Sattar N, Vijapurkar U, Desai M, et al. Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes. J Am Coll Cardiol. 2017;70(6):704\u201312.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"4018_CR117","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","volume":"10","author":"T Kadowaki","year":"2022","unstructured":"Kadowaki T, Isendahl J, Khalid U, Lee SY, Nishida T, Ogawa W, et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022;10(3):193\u2013206.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"4018_CR118","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1080\/14740338.2020.1694659","volume":"19","author":"K Kaku","year":"2020","unstructured":"Kaku K, Chin R, Naito Y, Iliev H, Ikeda R, Ochiai K, et al. Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: interim analysis from a post-marketing surveillance study. Expert Opin Drug Saf. 2020;19(2):211\u201321.","journal-title":"Expert Opin Drug Saf"},{"issue":"9","key":"4018_CR119","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/S2213-8587(21)00180-7","volume":"9","author":"MN Kosiborod","year":"2021","unstructured":"Kosiborod MN, Esterline R, Furtado RHM, Oscarsson J, Gasparyan SB, Koch GG, et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021;9(9):586\u201394.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"4018_CR120","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/j.clinthera.2015.05.511","volume":"37","author":"CS Kovacs","year":"2015","unstructured":"Kovacs CS, Seshiah V, Merker L, Christiansen AV, Roux F, Salsali A, et al. Empagliflozin as add-on therapy to pioglitazone with or without metformin in patients with type 2 diabetes mellitus. Clin Ther. 2015;37(8):1773-88 e1.","journal-title":"Clin Ther"},{"issue":"1","key":"4018_CR121","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s13195-024-01573-x","volume":"16","author":"I Koychev","year":"2024","unstructured":"Koychev I, Reid G, Nguyen M, Mentz RJ, Joyce D, Shah SH, et al. Inflammatory proteins associated with Alzheimer\u2019s disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial. Alzheimers Res Ther. 2024;16(1):212.","journal-title":"Alzheimers Res Ther"},{"issue":"12","key":"4018_CR122","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1007\/s00125-013-3039-1","volume":"56","author":"FJ Lavalle-Gonzalez","year":"2013","unstructured":"Lavalle-Gonzalez FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56(12):2582\u201392.","journal-title":"Diabetologia"},{"issue":"2","key":"4018_CR123","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s13300-023-01515-0","volume":"15","author":"BW Lee","year":"2024","unstructured":"Lee BW, Cho YM, Kim SG, Ko SH, Lim S, Dahaoui A, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as metformin add-on in a Korean population with type 2 diabetes. Diabetes Ther. 2024;15(2):547\u201363.","journal-title":"Diabetes Ther"},{"issue":"8","key":"4018_CR124","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/dom.12666","volume":"18","author":"LA Leiter","year":"2016","unstructured":"Leiter LA, Cefalu WT, de Bruin TW, Xu J, Parikh S, Johnsson E, et al. Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease. Diabetes Obes Metab. 2016;18(8):766\u201374.","journal-title":"Diabetes Obes Metab"},{"issue":"14","key":"4018_CR125","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.020734","volume":"10","author":"Q Li","year":"2021","unstructured":"Li Q, Jia M, Yan Z, Li Q, Sun F, He C, et al. Activation of glucagon-like peptide-1 receptor ameliorates cognitive decline in type 2 diabetes mellitus through a metabolism-independent pathway. J Am Heart Assoc. 2021;10(14): e020734.","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"4018_CR126","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.3624","volume":"14","author":"J Liu","year":"2024","unstructured":"Liu J, Shi X, Shao Y. Sodium-glucose cotransporter 1\/2 inhibition and risk of neurodegenerative disorders: a Mendelian randomization study. Brain Behav. 2024;14(7): e3624.","journal-title":"Brain Behav"},{"issue":"5","key":"4018_CR127","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S2213-8587(18)30023-8","volume":"6","author":"B Ludvik","year":"2018","unstructured":"Ludvik B, Frias JP, Tinahones FJ, Wainstein J, Jiang H, Robertson KE, et al. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2018;6(5):370\u201381.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"4018_CR128","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.2337\/dc15-0779","volume":"38","author":"C Mathieu","year":"2015","unstructured":"Mathieu C, Ranetti AE, Li D, Ekholm E, Cook W, Hirshberg B, et al. Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes. Diabetes Care. 2015;38(11):2009\u201317.","journal-title":"Diabetes Care"},{"issue":"13","key":"4018_CR129","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","volume":"390","author":"WG Meissner","year":"2024","unstructured":"Meissner WG, Remy P, Giordana C, Maltete D, Derkinderen P, Houeto JL, et al. Trial of lixisenatide in early Parkinson\u2019s disease. N Engl J Med. 2024;390(13):1176\u201385.","journal-title":"N Engl J Med"},{"issue":"4","key":"4018_CR130","doi-asserted-by":"publisher","first-page":"485","DOI":"10.2337\/dc16-2143","volume":"40","author":"GS Meneilly","year":"2017","unstructured":"Meneilly GS, Roy-Duval C, Alawi H, Dailey G, Bellido D, Trescoli C, et al. Lixisenatide therapy in older patients with type 2 diabetes inadequately controlled on their current antidiabetic treatment: the GetGoal-o randomized trial. Diabetes Care. 2017;40(4):485\u201393.","journal-title":"Diabetes Care"},{"issue":"1","key":"4018_CR131","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s41687-023-00577-9","volume":"7","author":"T Morel","year":"2023","unstructured":"Morel T, Cleanthous S, Andrejack J, Barker RA, Biagioni M, Blavat G, et al. Development and early qualitative evidence of two novel patient-reported outcome instruments to assess daily functioning in people with early-stage Parkinson\u2019s. J Patient Rep Outcomes. 2023;7(1):40.","journal-title":"J Patient Rep Outcomes"},{"issue":"7","key":"4018_CR132","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S2213-8587(19)30192-5","volume":"7","author":"O Mosenzon","year":"2019","unstructured":"Mosenzon O, Blicher TM, Rosenlund S, Eriksson JW, Heller S, Hels OH, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):515\u201327.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"4018_CR133","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/S2213-8587(23)00388-1","volume":"12","author":"Y Mu","year":"2024","unstructured":"Mu Y, Bao X, Eliaschewitz FG, Hansen MR, Kim BT, Koroleva A, et al. Efficacy and safety of once weekly semaglutide 2.4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2024;12(3):184\u201395.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"8","key":"4018_CR134","doi-asserted-by":"publisher","first-page":"741","DOI":"10.2174\/1567205016666190913155950","volume":"16","author":"RJ Mullins","year":"2019","unstructured":"Mullins RJ, Mustapic M, Chia CW, Carlson O, Gulyani S, Tran J, et al. A pilot study of exenatide actions in Alzheimer\u2019s disease. Curr Alzheimer Res. 2019;16(8):741\u201352.","journal-title":"Curr Alzheimer Res"},{"issue":"1","key":"4018_CR135","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2337\/dc08-1355","volume":"32","author":"M Nauck","year":"2009","unstructured":"Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32(1):84\u201390.","journal-title":"Diabetes Care"},{"issue":"2","key":"4018_CR136","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s00125-015-3795-1","volume":"59","author":"MA Nauck","year":"2016","unstructured":"Nauck MA, Stewart MW, Perkins C, Jones-Leone A, Yang F, Perry C, et al. Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetologia. 2016;59(2):266\u201374.","journal-title":"Diabetologia"},{"issue":"1","key":"4018_CR137","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12268","volume":"8","author":"CH Norgaard","year":"2022","unstructured":"Norgaard CH, Friedrich S, Hansen CT, Gerds T, Ballard C, Moller DV, et al. Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers. Alzheimers Dement (N Y). 2022;8(1): e12268.","journal-title":"Alzheimers Dement (N Y)"},{"key":"4018_CR138","doi-asserted-by":"crossref","unstructured":"Osmanovic Barilar J, Babic Perhoc A, Knezovic A, Homolak J, Virag D, Salkovic-Petrisic M. The effect of the sodium-glucose cotransporter inhibitor on cognition and metabolic parameters in a rat model of sporadic Alzheimer's disease.\u00a0Biomedicines . 2023;11(4):1025.","DOI":"10.3390\/biomedicines11041025"},{"issue":"15","key":"4018_CR139","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"issue":"7","key":"4018_CR140","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/dom.12647","volume":"18","author":"J Parkinson","year":"2016","unstructured":"Parkinson J, Tang W, Johansson CC, Boulton DW, Hamren B. Comparison of the exposure-response relationship of dapagliflozin in adult and paediatric patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2016;18(7):685\u201392.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"4018_CR141","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/S2213-8587(19)30194-9","volume":"7","author":"TR Pieber","year":"2019","unstructured":"Pieber TR, Bode B, Mertens A, Cho YM, Christiansen E, Hertz CL, et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):528\u201339.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"4018_CR142","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s00125-014-3196-x","volume":"57","author":"D Polidori","year":"2014","unstructured":"Polidori D, Mari A, Ferrannini E. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. Diabetologia. 2014;57(5):891\u2013901.","journal-title":"Diabetologia"},{"issue":"10192","key":"4018_CR143","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","volume":"394","author":"R Pratley","year":"2019","unstructured":"Pratley R, Amod A, Hoff ST, Kadowaki T, Lingvay I, Nauck M, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019;394(10192):39\u201350.","journal-title":"Lancet"},{"issue":"4","key":"4018_CR144","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S2213-8587(13)70214-6","volume":"2","author":"RE Pratley","year":"2014","unstructured":"Pratley RE, Nauck MA, Barnett AH, Feinglos MN, Ovalle F, Harman-Boehm I, et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol. 2014;2(4):289\u201397.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"4018_CR145","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.2337\/dc19-0883","volume":"42","author":"HW Rodbard","year":"2019","unstructured":"Rodbard HW, Rosenstock J, Canani LH, Deerochanawong C, Gumprecht J, Lindberg SO, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care. 2019;42(12):2272\u201381.","journal-title":"Diabetes Care"},{"issue":"3","key":"4018_CR146","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S2213-8587(13)70084-6","volume":"1","author":"M Roden","year":"2013","unstructured":"Roden M, Weng J, Eilbracht J, Delafont B, Kim G, Woerle HJ, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013;1(3):208\u201319.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4018_CR147","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.742873","volume":"12","author":"M Rodgers","year":"2021","unstructured":"Rodgers M, Migdal AL, Rodriguez TG, Chen ZZ, Nath AK, Gerszten RE, et al. Weight loss outcomes among early high responders to exenatide treatment: a randomized, placebo controlled study in overweight and obese women. Front Endocrinol (Lausanne). 2021;12: 742873.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"15","key":"4018_CR148","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1001\/jama.2019.2942","volume":"321","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, Allison D, Birkenfeld AL, Blicher TM, Deenadayalan S, Jacobsen JB, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. 2019;321(15):1466\u201380.","journal-title":"JAMA"},{"issue":"8","key":"4018_CR149","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.2337\/dc14-0001","volume":"37","author":"J Rosenstock","year":"2014","unstructured":"Rosenstock J, Fonseca VA, Gross JL, Ratner RE, Ahren B, Chow FC, et al. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. Diabetes Care. 2014;37(8):2317\u201325.","journal-title":"Diabetes Care"},{"issue":"14","key":"4018_CR150","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414\u201325.","journal-title":"JAMA"},{"issue":"2","key":"4018_CR151","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, O\u2019Neil PM, Rosenstock J, Sorrig R, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138\u201350.","journal-title":"JAMA"},{"issue":"9","key":"4018_CR152","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.2337\/dc12-2491","volume":"36","author":"G Schernthaner","year":"2013","unstructured":"Schernthaner G, Gross JL, Rosenstock J, Guarisco M, Fu M, Yee J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013;36(9):2508\u201315.","journal-title":"Diabetes Care"},{"key":"4018_CR153","doi-asserted-by":"crossref","unstructured":"Selvarajah V, Robertson D, Hansen L, Jermutus L, Smith K, Coggi A, et al. A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease.\u00a0Kidney Int. 2024;106(6):1170\u201380.","DOI":"10.1016\/j.kint.2024.08.023"},{"key":"4018_CR154","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-079475","volume":"386","author":"A Shin","year":"2024","unstructured":"Shin A, Koo BK, Lee JY, Kang EH. Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40\u201369 years with type 2 diabetes: population based cohort study. BMJ. 2024;386: e079475.","journal-title":"BMJ"},{"issue":"3","key":"4018_CR155","doi-asserted-by":"publisher","first-page":"147916412210981","DOI":"10.1177\/14791641221098168","volume":"19","author":"WZ Siao","year":"2022","unstructured":"Siao WZ, Lin TK, Huang JY, Tsai CF, Jong GP. The association between sodium-glucose cotransporter 2 inhibitors and incident dementia: a nationwide population-based longitudinal cohort study. Diab Vasc Dis Res. 2022;19(3):14791641221098168.","journal-title":"Diab Vasc Dis Res"},{"issue":"4","key":"4018_CR156","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41591-022-01703-8","volume":"28","author":"JA Spertus","year":"2022","unstructured":"Spertus JA, Birmingham MC, Nassif M, Damaraju CV, Abbate A, Butler J, et al. The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. Nat Med. 2022;28(4):809\u201313.","journal-title":"Nat Med"},{"issue":"5","key":"4018_CR157","doi-asserted-by":"publisher","first-page":"e2347","DOI":"10.1210\/clinem\/dgaa748","volume":"106","author":"AG Stack","year":"2021","unstructured":"Stack AG, Han D, Goldwater R, Johansson S, Dronamraju N, Oscarsson J, et al. Dapagliflozin added to verinurad plus febuxostat further reduces serum uric acid in hyperuricemia: the QUARTZ study. J Clin Endocrinol Metab. 2021;106(5):e2347\u201356.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"4018_CR158","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1185\/03007995.2013.850066","volume":"30","author":"K Stenlof","year":"2014","unstructured":"Stenlof K, Cefalu WT, Kim KA, Jodar E, Alba M, Edwards R, et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin. 2014;30(2):163\u201375.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"4018_CR159","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","volume":"6","author":"KR Tuttle","year":"2018","unstructured":"Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018;6(8):605\u201317.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"4018_CR160","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.2337\/dc21-2034","volume":"45","author":"KR Tuttle","year":"2022","unstructured":"Tuttle KR, Levin A, Nangaku M, Kadowaki T, Agarwal R, Hauske SJ, et al. Safety of empagliflozin in patients with type 2 diabetes and chronic kidney disease: pooled analysis of placebo-controlled clinical trials. Diabetes Care. 2022;45(6):1445\u201352.","journal-title":"Diabetes Care"},{"issue":"8","key":"4018_CR161","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.2337\/dc13-2759","volume":"37","author":"G Umpierrez","year":"2014","unstructured":"Umpierrez G, Tofe Povedano S, Perez Manghi F, Shurzinske L, Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014;37(8):2168\u201376.","journal-title":"Diabetes Care"},{"issue":"8","key":"4018_CR162","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0255726","volume":"16","author":"C Vaccari","year":"2021","unstructured":"Vaccari C, Grotto D, Pereira TDV, de Camargo JLV, Lopes LC. GLP-1 and GIP receptor agonists in the treatment of Parkinson\u2019s disease: translational systematic review and meta-analysis protocol of clinical and preclinical studies. PLoS One. 2021;16(8): e0255726.","journal-title":"PLoS One"},{"issue":"6","key":"4018_CR163","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1038\/s41366-020-0535-5","volume":"44","author":"F Vadini","year":"2020","unstructured":"Vadini F, Simeone PG, Boccatonda A, Guagnano MT, Liani R, Tripaldi R, et al. Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study. Int J Obes (Lond). 2020;44(6):1254\u201363.","journal-title":"Int J Obes (Lond)"},{"issue":"3","key":"4018_CR164","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","volume":"28","author":"AA Voors","year":"2022","unstructured":"Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568\u201374.","journal-title":"Nat Med"},{"issue":"14","key":"4018_CR165","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403\u201313.","journal-title":"JAMA"},{"key":"4018_CR166","doi-asserted-by":"publisher","first-page":"2682657","DOI":"10.1155\/2019\/2682657","volume":"2019","author":"J Wang","year":"2019","unstructured":"Wang J, Li HQ, Xu XH, Kong XC, Sun R, Jing T, et al. The effects of once-weekly dulaglutide and insulin glargine on glucose fluctuation in poorly oral-antidiabetic controlled patients with type 2 diabetes mellitus. Biomed Res Int. 2019;2019:2682657.","journal-title":"Biomed Res Int"},{"key":"4018_CR167","doi-asserted-by":"publisher","DOI":"10.2196\/58137","volume":"9","author":"X Wang","year":"2024","unstructured":"Wang X, Plantinga AM, Xiong X, Cromer SJ, Bonzel CL, Panickan V, et al. Comparing insulin against glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter 2 inhibitors on 5-year incident heart failure risk for patients with type 2 diabetes mellitus: real-world evidence study using insurance claims. JMIR Diabetes. 2024;9: e58137.","journal-title":"JMIR Diabetes"},{"key":"4018_CR168","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.bbr.2018.08.006","volume":"356","author":"KT Watson","year":"2019","unstructured":"Watson KT, Wroolie TE, Tong G, Foland-Ross LC, Frangou S, Singh M, et al. Neural correlates of liraglutide effects in persons at risk for Alzheimer\u2019s disease. Behav Brain Res. 2019;356:271\u20138.","journal-title":"Behav Brain Res"},{"issue":"9","key":"4018_CR169","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/dom.12479","volume":"17","author":"RS Weinstock","year":"2015","unstructured":"Weinstock RS, Guerci B, Umpierrez G, Nauck MA, Skrivanek Z, Milicevic Z. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study. Diabetes Obes Metab. 2015;17(9):849\u201358.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"4018_CR170","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1007\/s00125-014-3360-3","volume":"57","author":"PN Weissman","year":"2014","unstructured":"Weissman PN, Carr MC, Ye J, Cirkel DT, Stewart M, Perry C, et al. HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea. Diabetologia. 2014;57(12):2475\u201384.","journal-title":"Diabetologia"},{"issue":"6","key":"4018_CR171","doi-asserted-by":"publisher","first-page":"405","DOI":"10.7326\/0003-4819-156-6-201203200-00003","volume":"156","author":"JP Wilding","year":"2012","unstructured":"Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156(6):405\u201315.","journal-title":"Ann Intern Med"},{"issue":"11","key":"4018_CR172","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002.","journal-title":"N Engl J Med"},{"issue":"2","key":"4018_CR173","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2337\/dc22-1705","volume":"46","author":"CY Wu","year":"2023","unstructured":"Wu CY, Iskander C, Wang C, Xiong LY, Shah BR, Edwards JD, et al. Association of sodium-glucose cotransporter 2 inhibitors with time to dementia: a population-based cohort study. Diabetes Care. 2023;46(2):297\u2013304.","journal-title":"Diabetes Care"},{"issue":"8","key":"4018_CR174","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.2337\/dc13-2760","volume":"37","author":"C Wysham","year":"2014","unstructured":"Wysham C, Blevins T, Arakaki R, Colon G, Garcia P, Atisso C, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014;37(8):2159\u201367.","journal-title":"Diabetes Care"},{"issue":"11","key":"4018_CR175","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/j.clinthera.2017.10.002","volume":"39","author":"M Yu","year":"2017","unstructured":"Yu M, Brunt KV, Milicevic Z, Varnado O, Boye KS. Patient-reported outcomes in patients with type 2 diabetes treated with dulaglutide added to titrated insulin glargine (AWARD-9). Clin Ther. 2017;39(11):2284\u201395.","journal-title":"Clin Ther"},{"issue":"1","key":"4018_CR176","doi-asserted-by":"publisher","first-page":"e12139","DOI":"10.1002\/trc2.12139","volume":"7","author":"B Zhou","year":"2021","unstructured":"Zhou B, Zissimopoulos J, Nadeem H, Crane MA, Goldman D, Romley JA. Association between exenatide use and incidence of Alzheimer\u2019s disease. Alzheimers Dement (N Y). 2021;7(1):e12139.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"4","key":"4018_CR177","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1021\/acschemneuro.0c00722","volume":"12","author":"HH Arab","year":"2021","unstructured":"Arab HH, Safar MM, Shahin NN. Targeting ROS-dependent AKT\/GSK-3beta\/NF-kappaB and DJ-1\/Nrf2 pathways by dapagliflozin attenuates neuronal injury and motor dysfunction in rotenone-induced Parkinson\u2019s disease rat model. ACS Chem Neurosci. 2021;12(4):689\u2013703.","journal-title":"ACS Chem Neurosci"},{"issue":"2","key":"4018_CR178","doi-asserted-by":"publisher","first-page":"a009399","DOI":"10.1101\/cshperspect.a009399","volume":"2","author":"L Stefanis","year":"2012","unstructured":"Stefanis L. alpha-Synuclein in Parkinson\u2019s disease. Cold Spring Harb Perspect Med. 2012;2(2):a009399.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"4018_CR179","doi-asserted-by":"publisher","first-page":"6880","DOI":"10.1038\/s41467-022-34555-4","volume":"13","author":"M Jin","year":"2022","unstructured":"Jin M, Matsumoto S, Ayaki T, Yamakado H, Taguchi T, Togawa N, et al. DOPAnization of tyrosine in alpha-synuclein by tyrosine hydroxylase leads to the formation of oligomers. Nat Commun. 2022;13(1):6880.","journal-title":"Nat Commun"},{"issue":"6","key":"4018_CR180","doi-asserted-by":"publisher","first-page":"4486","DOI":"10.1007\/s12035-016-9988-x","volume":"54","author":"A Stojakovic","year":"2017","unstructured":"Stojakovic A, Paz-Filho G, Arcos-Burgos M, Licinio J, Wong ML, Mastronardi CA. Role of the IL-1 pathway in dopaminergic neurodegeneration and decreased voluntary movement. Mol Neurobiol. 2017;54(6):4486\u201395.","journal-title":"Mol Neurobiol"},{"issue":"1","key":"4018_CR181","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12933-024-02294-z","volume":"23","author":"DD Wang","year":"2024","unstructured":"Wang DD, Naumova AV, Isquith D, Sapp J, Huynh KA, Tucker I, et al. Dapagliflozin reduces systemic inflammation in patients with type 2 diabetes without known heart failure. Cardiovasc Diabetol. 2024;23(1):197.","journal-title":"Cardiovasc Diabetol"},{"key":"4018_CR182","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12933-015-0297-x","volume":"14","author":"P Fioretto","year":"2015","unstructured":"Fioretto P, Giaccari A, Sesti G. Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus. Cardiovasc Diabetol. 2015;14:142.","journal-title":"Cardiovasc Diabetol"},{"issue":"22","key":"4018_CR183","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.3390\/cells13221876","volume":"13","author":"A Tanvir","year":"2024","unstructured":"Tanvir A, Jo J, Park SM. Targeting glucose metabolism: a novel therapeutic approach for Parkinson\u2019s disease. Cells. 2024;13(22):1876.","journal-title":"Cells"},{"issue":"2","key":"4018_CR184","doi-asserted-by":"publisher","first-page":"e009417","DOI":"10.1136\/bmjopen-2015-009417","volume":"6","author":"DS Shyangdan","year":"2016","unstructured":"Shyangdan DS, Uthman OA, Waugh N. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ Open. 2016;6(2):e009417.","journal-title":"BMJ Open"},{"key":"4018_CR185","doi-asserted-by":"publisher","first-page":"100158","DOI":"10.1016\/j.dscb.2024.100158","volume":"15","author":"MA Bantounou","year":"2024","unstructured":"Bantounou MA, Shoaib K, Mazzoleni A, Modalavalasa H, Kumar N, Philip S. The association between type 2 diabetes mellitus and Parkinson\u2019s disease; a systematic review and meta-analysis. Brain Disorders. 2024;15:100158.","journal-title":"Brain Disorders"},{"issue":"1","key":"4018_CR186","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1172\/JCI200317522","volume":"111","author":"S Przedborski","year":"2003","unstructured":"Przedborski S, Vila M, Jackson-Lewis V. Neurodegeneration: what is it and where are we? J Clin Invest. 2003;111(1):3\u201310.","journal-title":"J Clin Invest"},{"key":"4018_CR187","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04018-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-04018-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04018-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T23:02:01Z","timestamp":1743980521000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-025-04018-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":187,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4018"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-04018-w","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]},"assertion":[{"value":"23 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no financial interests or potential conflicts of interest. The Institutional Review Board of the Tri-Service General Hospital has confirmed that no ethical approval is required (TSGHIRB: B-109\u201329). The current study did not directly involve individual participant so that we did not have the chance to approach individual participant or explore individual participant\u2019s information. Therefore, it would be impossible to obtain consent to participate in the current study.The authors of this work were supported by the following grants: Brendon Stubbs is supported by the NIHR. Brendon Stubbs is part funded by the NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust. Brendon Stubbs is also supported by the Maudsley Charity, King\u2019s College London.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The current study did not directly involve individual participant so that we did not have the chance to approach individual participant or explore individual participant\u2019s information. Therefore, it would be impossible to obtain consent to publish in the current study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"197"}}